Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination
Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination
复制标题
DOI：
10.1016/j.vetimm.2006.01.008
复制
发表时间：
2006-05-15
影响因子：
1.8
通讯作者：
Audonnet, JC
中科院分区：
文献类型：
--
作者：
Minke, JM;Fischer, L;Audonnet, JC
在这项研究中，实验金丝雀痘病毒（ALVAC）和质粒DNA重组疫苗表达的gB，gC和gD糖蛋白的EHV-1的能力，以保护传统的小马对呼吸挑战EHV-1进行了评估。此外，还探索了增强马对ALVAC和DNA疫苗接种的血清学应答的潜在方法。这些包括抗原与常规佐剂的共施用、与DMRIE-DOPE的复合以及抗原沿着马GM-CSF的共表达。EHV致敏小马组以5周间隔肌内接种一剂适当的试验疫苗两次。在第二次接种后2 - 3周，用EHV-1的强AM毒株鼻内感染小马，然后对它们进行临床观察并取样进行病毒学研究。结果表明，DNA和ALVAC疫苗接种显着减少病毒排泄后的挑战，在持续时间和幅度，但未能防止细胞相关的病毒血症。值得注意的是，在存在Carbopol佐剂或磷酸铝配制的DNA质粒的情况下，接种ALVAC-EHV的小马组几乎完全没有病毒排泄。在存在GM-CSF的情况下施用DNA疫苗并在DMRIE-DOPE中配制，以及在存在Carbopol佐剂的情况下施用ALVAC疫苗显著改善了对EHV-1的病毒中和抗体应答。这些研究结果表明，DNA和ALVAC疫苗接种是一种很有前途的免疫控制EHV-1感染的方法，但需要更多的研究来确定EHV-1的免疫显性保护性抗原及其与马免疫系统的相互作用。(c)2006年由Elsevier B. V.出版
In this study, experimental canarypox virus (ALVAC) and plasmid DNA recombinant vaccines expressing the gB, gC and gD glycoproteins of EHV-1 were assessed for their ability to protect conventional ponies against a respiratory challenge with EHV-1. In addition, potential means of enhancing serological responses in horses to ALVAC and DNA vaccination were explored. These included co-administration of the antigen with conventional adjuvants, complexation with DMRIE-DOPE and coexpression of the antigen along with equine GM-CSF. Groups of EHV primed ponies were vaccinated twice intra-muscularly with one dose of the appropriate test vaccine at an interval of 5 weeks. Two to 3 weeks after the second vaccination, ponies were infected intra-nasally with the virulent AM strain of EHV-1 after which they were observed clinically and sampled for virological investigations. The results demonstrated that DNA and ALVAC vaccination markedly reduced virus excretion after challenge in terms of duration and magnitude, but failed to protect against cell-associated virenitia. Noteworthy was the almost complete absence of virus excretion in the group of ponies vaccinated with ALVAC-EHV in the presence of Carbopol adjuvant or DNA plasmid formulated with aluminium phosphate. The administration of the DNA vaccine in the presence of GM-CSF and formulated in DMRIE-DOPE and of the ALVAC vaccine in the presence of Carbopol adjuvant significantly improved virus neutralising antibody responses to EHV-1. These findings indicate that DNA and ALVAC vaccination is a promising approach for the immunological control of EHV-1 infection, but that more research is needed to identify the immunodominant protective antigens of EHV-1 and their interaction with the equine immune system. (c) 2006 Published by Elsevier B.V.